Clinical Trial

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

Study acronym: MAOP3
Not Yet Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated March 29, 2021 (before its estimated January 1, 2022 completion). Its status may not reflect the trial's current state.
Summary
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III clinical trial. It will be conducted at selected investigational sites globally. The study is comprised of 2 parts.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-01-13; most recent amendment 2023-05-15.
Status change: Not Yet Recruiting → Terminated 2023-05-15
Trial Details
NCT Number NCT04709328
Lead Sponsor Sinocelltech Ltd.
Conditions COVID-19, SARS-CoV-2
Enrollment 690 participants
Start Date 2021-03-28
Primary Completion 2022-01-01 (estimated)
Study Completion 2022-03-01 (estimated)
Updated on ClinicalTrials.gov 2021-03-29